Supplementary Figures S1-S3 and Suppl. Tables S1-S2 from AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor–Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment
Year: 2023
Type: supplementary-materials
Abstract: Supplemental tables S1-S2: (S1) sequences of sgRNA for CRISPR-cas9 knock out cell lines. (S2) Fraction of oxygen consumption rate remaining after tamoxifen treatment at 30μM in cancer cell lines Supplemental Figures S1-S3: (S1) Oxygen consumption measurements of Tamoxifen, 4OH-Tamoxifen, and fulvestrant treatment, oxygen consumption of MCF7 cells treated with DMSO or fulvestrant plus tamoxifen and Immunoblot of ER expression with fulvestrant treatment, oxygen consumption measurements of mitochondria isolated from mouse liver treated with tamoxifen, clonogenic survival of MDA-231 cells treated with tamoxifen +/- Glucose and +/- methyl succinate, immunoblot of AMPK activation in the presence of glucose or 2DG and survival of BC cells treated with 2DG or 3BP. (S2) LC-MS/MS quantification of acyl-CoA species after tamoxifen treatment compared to control and BODPIY staining of MDA-231 cells treated with tamoxifen or DMSO control. (S3) Clonogenic survival and immunoblot of MCF7 shNT and shAMPK cells treated with 30μM tamoxifen, survival assays of MDA-231 cells with different AMPK status's following tamoxifen treatment, and autoradiograph film of 35S labeling in MDA-231 cells and MDA-231 crspAMPKα1.
Authors: Natalie A. Daurio, Stephen W. Tuttle, Andrew J. Worth, Ethan Y. Song, Julianne M. Davis, Nathaniel W. Snyder, Ian A. Blair, Constantinos Koumenis
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4361875303